Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

UPDATE TO THE NOTICE TO FISKARS CORPORATION ANNUAL GENERAL MEETING

Fiskars CorporationStock Exchange ReleaseFebruary 13, 2023 at 6:00 p.m. EET UPDATE TO THE NOTICE TO FISKARS CORPORATION ANNUAL GENERAL MEETING Fiskars Corporation updates section 8 (Resolution on the use of the profit shown on the balance sheet and the payment of dividend) in the notice to the Annual General Meeting published on February 7, 2023, with respect to the schedule for the second dividend instalment. The notice is updated due to a change to the schedule of the system update in September, communicated by Euroclear Finland Oy on February 9, 2023. In its updated form,

Hunter Group ASA - Mandatory notification of trade by primary insiders

Oslo, 13 February 2023 AF Capital AS, a company wholly owned by board member Mr. Arne Fredly has sold 100,000,000 shares in Hunter Group ASA (the “Company”) at the price of NOK 0.0675 per share. Upon completion of the transaction, AF Capital AS, or any other entities affiliated with Mr. Fredly, will hold zero shares, zero warrants, and no remaining financial interests in the Company and Mr. Fredly will resign from the board of directors of the Company as soon as a replacement has been identified. The price is equal to the estimated net liquidity of the Company, leaving the Company

ExpreS2ion will present fourth quarter and full-year 2022 results

Hørsholm, Denmark, February 13, 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") is pleased to announce that it will present fourth quarter and full-year 2022 results via webcast on February 15th, 2023, at 14:30 CET.By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS[2] technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company’s website .

Arctic Bioscience – Mandatory notification of trade

Christer Valderhaug, CEO in Arctic Bioscience, has today bought 27.630 shares in Arctic Bioscience at an average price of NOK 10,8342 per share. Following the transaction, Christer Valderhaug holds 47.630 shares and 250.000 share options in Arctic Bioscience.Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR) article 19 number 3 and the Norwegian Securities Trading Act § 5-12.

Wirtek changes expectations for 2022 and announces expectations for 2023

Company announcement no. 1/202313 February 2023 This announcement contains inside information Fiscal year 2022 The Board of Directors for Wirtek A/S clarifies and decreases the financial expectations for 2022 based on preliminary and non-audited financial results for the fiscal year 2022: · Revenue is expected at DKK 65.7m, corresponding to a growth of 45% compared to 2021. The revenue is within the latest announced range of DKK 64.0m – 69.0m. · The EBITDA expectation is decreased to DKK 7.1m – 7.5m, a growth of 14% - 20% compared to 2021. The adjusted EBITDA is below the

#23-52 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Invitation to Fourth Quarter 2022 Results

Oslo, 13 February 2023: Norwegian Energy Company ASA ("Noreco" or the "Company") will publish its financial results for the fourth quarter and full year of 2022 on Wednesday 15 February 2023 at 07:00 (CET). A webcast presentation, followed by a Q&A session, will be hosted at 11:00 (CET). To join webcast: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230215_12  *** Contact: Cathrine Torgersen, EVP Investor Relations & ESGEmail: ct@noreco.comPhone: +47 915 28 501

Midsona praised for sustainability work

Midsona AB (publ) today announces that the company has won the title as the stock exchange's most sustainable company in the daily goods category and comes in third place overall in the annual ranking Sustainable Companies 2022.For the fifth year in a row, Lund University, Dagens Industri and Aktuell Hållbarhet have reviewed the sustainability work of large publicly listed companies. The survey has examined a total of 131 Swedish listed companies' sustainability work during the period May to August 2022 with a focus on risk and governance. "The sustainability perspective is an important

Everfuel awarded follow-up order to increase capacity at Wuppertal bus station in Germany

Herning, Denmark, 13 February 2023 – Everfuel is pleased to announce that the company has received a follow-up order from WSW mobil GmbH for increased capacity and scope for the planned heavy-duty hydrogen fuelling station in Wuppertal, Germany. In April 2022, after a European-wide tendering procedure, WSW mobil GmbH awarded Everfuel GmbH the contract for a hydrogen fueling station to serve a fleet of fuel cell buses for public transportation. The follow-up order announced today consists of an increase in hardware and associated services. It is the third contract in Germany for

Listen to a patient story: His brain tumor was removed with laser – at home after two days

This weekend the local TV news send an interview with one of the patients treated in the ongoing CLS-sponsored study at Skåne University Hospital, in Lund, Sweden. A hard-to-reach brain tumor was removed and already two days after the operation, the patient was able to go home.The story of this patient is that just over two years ago, he first underwent traditional surgery, in which the skull bone was opened. In January this year, he suffered a cancer relapse when a new brain tumour was discovered. This time the opportunity to participate in a new study in Lund appeared and he became the

#23-18 Rights issue in Sotkamo Silver AB

The board of Sotkamo Silver AB (“the Company”) has decided on a rights issue with preferential rights for the Company’s existing shareholders subject to approval from the extraordinary general meeting, to be held on February 16, 2023. The last day of trading in the Company’s shares including the right to receive subscription rights is February 16, 2023. The first day of trading in the Company’s shares excluding the right to receive subscription rights is February 17, 2023. The record date is February 20, 2023. The shareholders of the Company will receive one (1) subscription right for

The Colour of Love - Valentine's Day Special

How to use the colour of love (red) in interior design.Valentine’s day is upon us and what better way to reign in the day of love than looking at all the fabulous ways you can use the colour of love in the home?   [A picture containing text Description automatically generated]   MyJobQuote’s  interior designer, Ryan McDonough, has rounded up some of the best ways to use red (the colour of love) throughout your home.   This versatile colour is one of the most passionate and bold colours to use in interior design. Let’s take a look at Ryan’s ideas:

Arctic Bioscience – Mandatory notification of trade

Ronja Capital II AS, a legal person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has today bought 40.000 shares in Arctic Bioscience at an average price of NOK 10,90 per share. Following the transaction, Ronja Capital II AS holds 2.144.166 shares in Arctic Bioscience.Member of the Board of Directors, Tore A. Tønseth, is Investment Director at Ronja Capital II AS. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR)

Director/PDMR Shareholding

13 February 2023 14:01 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 9 February 2023, an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the AstraZeneca Investment Plan (AZIP) vested to Pascal Soriot, Executive Director and Chief Executive Officer. The AZIP award was granted on 27 March 2015 and was subject to a four-year performance period followed by a four-year holding period before vesting. Application of the performance measures specified at the time of grant resulted in 75% of

AddLife strengthens the organization for future growth

AddLife develops the organization to take advantage of future growth opportunities and strengthens the support to the portfolio companies by adding internally recruited resources with solid international operational experience. "AddLife has grown significantly in recent years and acquired several major companies in Europe within multiple new segments. With this new and strengthened position, AddLife has gained access to many new growth opportunities and has also added new and highly competent international teams in the various companies. AddLife is now developing an organization for

Director/PDMR Shareholding

13 February 2023 14:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that on 9 February 2023 certain awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) and the Company's American Depositary Shares (ADSs) vested to Dr Aradhana Sarin, Executive Director and Chief Financial Officer. Each ADS represents one half of an Ordinary Share. Following the reinvestment of dividends and the withholding to satisfy certain tax obligations arising on vesting, Dr Sarin acquired the ADSs and Ordinary Shares as detailed

Year-end Report 2022: Profits strong but continued uncertainty going forward

LKAB is reporting operating profit for full year 2022 of nearly SEK 21 billion, representing an operating margin of 45 percent. This despite increased costs from factors such as higher energy prices and disruptions in production.Net sales for full year 2022 amounted to MSEK 46,543 (48,812) and were impacted mainly by lower prices for highly upgraded iron ore products and lower delivery volumes; these were offset, however, by a strong dollar exchange rate. For the fourth quarter net sales amounted to MSEK 9,949 (9,064), with a higher dollar rate compensating for lower delivery volumes.

Supporting Staffordshire manufacturers through innovation

It’s the final call for Staffordshire businesses to apply for a unique opportunity to collaborate with Staffordshire UniversityThe Staffordshire Advanced Manufacturing, Prototyping and Innovation Demonstrator (SAMPID)  project supports local manufacturers to develop products, prototypes and improve processes using cutting edge equipment. Each bespoke partnership is fully funded and supported by a student or graduate alongside a dedicated academic expert.

SaltX enters industrialization - invests SEK 50 million in a new demonstration facility

After successful and verified tests for manufacturing climate-neutral lime and a "pre-order" of the first factory from SMA Mineral, the company is now investing circa fifty million in a demonstration plant to industrialize the technology for electric calcination.Since the fall of 2021, SaltX Technology has been conducting test operations for its electric calcination technology EAC (Electric Arc Calciner). In 2022, the company scaled up its operations to a pilot facility. After successful tests to produce climate-neutral lime and cement clinker, as well as several orders for material tests,

Groundbreaking for Cinis Fertilizer production facility in Örnsköldsvik

Three people participated when Cinis Fertilizer hosted a ceremonial ground­breaking to officially kick off the construction of its plant in Köpmanholmen in Örnsköldsvik. At the site, the company will manufacture environmentally friendly mineral fertilizer from the beginning of 2024.Today, Cinis Fertilizers CEO Jakob Liedberg, together with the chairman of Örnsköldsvik’s municipal board, Anna-Britta Åkerlind, and We Construction CEO Jonas Lindén, took a symbolic first sod in Köpmanholmen. The spade was taken with a common spade with three handles. - What we are going to build here in

INVISIO Year-end bulletin 2022: Back on the growth track – record high sales

CEO comment“There was a strong close to the year. Order intake in the last quarter amounted to almost SEK 300 million and sales to about SEK 290 million, the latter being the highest ever in a single quarter. The company is starting 2023 with a record-high order book of more than SEK 625 million. At the same time profitability has strengthened, the operating margin exceeds 20 per cent. The extensive forward-looking investments carried out in recent years relating to broadening the product portfolio, acquiring Racal Acoustics and streng­thening both the R&D and sales organizations, have

Camurus withdraws variation application for CAM2038 to include chronic pain

Lund, Sweden — 13 February 2023 — Camurus (NASDAQ STO: CAMX) announced today that it has notified the European Medicines Agency (EMA) of its decision to withdraw the Type II variation application for CAM2038 to include treatment of chronic pain in patients with opioid dependence. The decision is based on Camurus’ assessment of the request from EMA’s Committee for Medicinal Products for Human Use (CHMP) for additional clinical data to support the proposed extended indication for CAM2038 (Buvidal[®]). The pivotal clinical program was aligned with representatives from EMA prior to

CS MEDICA engages a Financial Advisor

CS MEDICA A/S (”CS MEDICA” or the ”Company”) announces today that the Company has entered into an agreement with the financial advisor Kapital Partner in Denmark.  With this cooperation, the company secures valuable insights and guidance on financial decisions and strategies as well as assistance in sourcing financial partners and maximizing shareholder value.As an efficient OTC alternative, CS MEDICA is currently first mover to bridge R&D with patent-pending products registered as medical devices with cannabidiol under the pharmaceutical regulation, Medical Device Directive (MDD), now

There are no items matching the current filter
There are no more items matching the current filter
Back to top